BRPI0410789A - moléculas de ácido nucleico, composto ou oligonucleotìdeo, composição farmacêutica, métodos para induzir a morte da célula pré-cancerosa ou cancerosa em células ou tecidos, para tratar um ser humano ou animal suspeito de ter pré-cáncer ou cáncer, para melhorar a eficácia de um tratamento de cáncer com medicamento quimioterapêutico e de hibridização para distinguir entre células normais, pré-cancerosas ou cancerosas, kit, e, método de hibridização in situ para determinar a localização da célula do rna quimérico mitocondrial anti-sentido ou sentido no citoplasma, núcleo e nucléolo das células presentes na amostra - Google Patents

moléculas de ácido nucleico, composto ou oligonucleotìdeo, composição farmacêutica, métodos para induzir a morte da célula pré-cancerosa ou cancerosa em células ou tecidos, para tratar um ser humano ou animal suspeito de ter pré-cáncer ou cáncer, para melhorar a eficácia de um tratamento de cáncer com medicamento quimioterapêutico e de hibridização para distinguir entre células normais, pré-cancerosas ou cancerosas, kit, e, método de hibridização in situ para determinar a localização da célula do rna quimérico mitocondrial anti-sentido ou sentido no citoplasma, núcleo e nucléolo das células presentes na amostra

Info

Publication number
BRPI0410789A
BRPI0410789A BRPI0410789-6A BRPI0410789A BRPI0410789A BR PI0410789 A BRPI0410789 A BR PI0410789A BR PI0410789 A BRPI0410789 A BR PI0410789A BR PI0410789 A BRPI0410789 A BR PI0410789A
Authority
BR
Brazil
Prior art keywords
cells
precancerous
cancer
cancerous
normal
Prior art date
Application number
BRPI0410789-6A
Other languages
English (en)
Inventor
Luis O Burzio
Jaime E Villegas
Veronica A Burzio
Original Assignee
Bios Chile I G S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33551438&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0410789(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bios Chile I G S A filed Critical Bios Chile I G S A
Publication of BRPI0410789A publication Critical patent/BRPI0410789A/pt
Publication of BRPI0410789B1 publication Critical patent/BRPI0410789B1/pt
Publication of BRPI0410789B8 publication Critical patent/BRPI0410789B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/708—Specific hybridization probes for papilloma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"MOLéCULAS DE áCIDO NUCLEICO, COMPOSTO OU OLIGONUCLEOTìDEO, COMPOSIçãO FARMACêUTICA, MéTODOS PARA INDUZIR A MORTE DA CéLULA PRé-CANCEROSA OU CANCEROSA EM CéLULAS OU TECIDOS, PARA TRATAR UM SER HUMANO OU ANIMAL SUSPEITO DE TER PRé-CáNCER OU CáNCER, PARA MELHORAR A EFICáCIA DE UM TRATAMENTO DE CáNCER COM MEDICAMENTO QUIMIOTERAPêUTICO E DE HIBRIDIZAçãO PARA DISTINGUIR ENTRE CéLULAS NORMAIS, PRé-CANCEROSAS OU CANCEROSAS, KIT, E, MéTODO DE HIBRIDIZAçãO IN SITU PARA DETERMINAR A LOCALIZAçãO DA CéLULA DO RNA QUIMéRICO MITOCONDRIAL ANTI-SENTIDO OU SENTIDO NO CITOPLASMA, NúCLEO E NUCLéOLO DAS CéLULAS PRESENTES NA AMOSTRA". Uma nova família de RNAs mitocondriais humanos, aludidos como RNAs quiméricos, que são diferencialmente expressados em células normais, pré-cancerosas e cancerosas, é descrita. Oligonucleotídeos cujos alvos são os RNAs quiméricos são fornecidos. Os oligonucleotídeos descritos ou seus análogos podem ser usado para diagnósticos do câncer e terapia do câncer assim como para pesquisa. Em uma forma de realização desta invenção, estes oligonucleotídeos hibridizam com os RNAs quiméricos mitocondriais sentido ou anti-sentido e o resultado da hibridização é útil para diferenciar entre células proliferativas normais, células pré-cancerosas e células cancerosas. Em uma outra forma de realização da invenção, as composições compreendem oligonucleotídeos que hibridizam com os RNAs quiméricos humanos resultando na morte da célula cancerosa e da célula cancerosa, enquanto não há nenhum efeito nas células normais, constituindo portanto, um novo método para a terapia do câncer.
BRPI0410789A 2003-05-21 2004-05-21 composição farmacêutica, uso de um ou mais oligonucleotídeos, e, método de detecção BRPI0410789B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47210603P 2003-05-21 2003-05-21
US60/472,106 2003-05-21
PCT/US2004/015929 WO2005001030A2 (en) 2003-05-21 2004-05-21 Markers for pre-cancer and cancer cells and the method to interfere with cell proliferation therein

Publications (3)

Publication Number Publication Date
BRPI0410789A true BRPI0410789A (pt) 2006-08-01
BRPI0410789B1 BRPI0410789B1 (pt) 2020-11-10
BRPI0410789B8 BRPI0410789B8 (pt) 2021-05-25

Family

ID=33551438

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410789A BRPI0410789B8 (pt) 2003-05-21 2004-05-21 composição farmacêutica, uso de um ou mais oligonucleotídeos, e, método de detecção

Country Status (13)

Country Link
US (6) US8318686B2 (pt)
EP (3) EP2270159B1 (pt)
JP (3) JP5201834B2 (pt)
AT (1) ATE506437T1 (pt)
BR (1) BRPI0410789B8 (pt)
CA (1) CA2526639C (pt)
DE (1) DE602004032329D1 (pt)
DK (3) DK2264170T3 (pt)
ES (3) ES2365511T3 (pt)
HU (1) HUE032575T2 (pt)
MX (1) MXPA05012620A (pt)
PL (3) PL2270159T3 (pt)
WO (1) WO2005001030A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5201834B2 (ja) 2003-05-21 2013-06-05 アンデス バイオテクノロジーズ ソシエダード アノニマ 前癌と癌細胞用のマーカー、及び前記細胞の増殖阻害方法
CA2585587C (en) * 2004-10-29 2016-02-16 Maarten Tjerk Penning Methods using mitochondrial nucleic acid for determining a health status of an individual
CN102589945B (zh) * 2012-02-16 2013-10-23 中国人民解放军第三军医大学第二附属医院 骨髓涂片存放盒
CN105283466A (zh) * 2013-03-14 2016-01-27 安第斯生物技术股份有限公司 用于检测和治疗多发性骨髓瘤的方法
WO2014153209A1 (en) * 2013-03-14 2014-09-25 Andes Biotechnologies S.A. Antisense oligonucletotides for treatment of cancer stem cells
WO2015066485A2 (en) * 2013-10-31 2015-05-07 The Children's Hospital Of Philadelphia Mitochondrial disease genetic diagnostics
CA2939860A1 (en) * 2014-03-14 2015-10-08 Andes Biotechnologies S.A. Pharmaceutical compositions comprising rna and use for treating cancer

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5644048A (en) 1992-01-10 1997-07-01 Isis Pharmaceuticals, Inc. Process for preparing phosphorothioate oligonucleotides
US6537973B1 (en) 1992-03-16 2003-03-25 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5646262A (en) 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
US6316210B1 (en) 1995-12-20 2001-11-13 Subsidiary No. 3, Inc. Genetic suppressor elements against human immunodeficiency virus
US6426412B1 (en) 1995-12-20 2002-07-30 Subsidiary No. 3, Inc. Nucleic acids encoding human immunodeficiency virus type 1 genetic suppressor elements
US5998203A (en) * 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US6720413B1 (en) 1997-03-04 2004-04-13 Musc Foundation For Research Development Methods and compositions for diagnosis and treatment of cancer
US6333152B1 (en) 1997-05-21 2001-12-25 The Johnshopkins University Gene expression profiles in normal and cancer cells
US6071743A (en) 1997-06-02 2000-06-06 Subsidiary No. 3, Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
US6537972B1 (en) 1997-06-02 2003-03-25 Subsidiary No. 3., Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
US6764822B1 (en) * 1997-09-19 2004-07-20 Sequenom, Inc. DNA typing by mass spectrometry with polymorphic DNA repeat markers
JP3251219B2 (ja) 1997-10-13 2002-01-28 雅嗣 田中 ヒトミトコンドリアｄｎａを用いた遺伝子検出方法
US6417169B1 (en) 1998-04-23 2002-07-09 Genesense Technologies Inc. Insulin-like growth factor II antisense oligonucleotide sequences and methods of using same to inhibit cell growth
US20030092063A1 (en) * 1998-05-15 2003-05-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1999065928A2 (en) 1998-06-19 1999-12-23 Genzyme Corporation Polynucleotide population isolated from non-metastatic and metastatic breast tumor tissues
US6280946B2 (en) 1998-08-07 2001-08-28 Boston Probes, Inc. PNA probes, probe sets, methods and kits pertaining to the universal detection of bacteria and eucarya
WO2000026363A1 (en) * 1998-11-04 2000-05-11 Genset GENOMIC AND COMPLETE cDNA SEQUENCES OF HUMAN ADIPOCYTE-SPECIFIC APM1 AND BIALLELIC MARKERS THEREOF
US6576759B2 (en) 1999-02-10 2003-06-10 Pangene Corporation Antisense inhibition of RAD51
EP1208225A2 (en) 1999-04-20 2002-05-29 Mitokor Single nucleotide polymorphisms in mitochondrial genes that segregate with alzheimer's disease
WO2001016323A2 (en) * 1999-09-01 2001-03-08 Subsidiary N0.3, Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
US6573050B1 (en) 1999-10-29 2003-06-03 Sunnybrook & Women's College Health Sciences Centre Treatment, diagnosis and evaluation of anti-cancer therapy resistance in melanoma
WO2001076532A2 (en) 2000-04-11 2001-10-18 Cogent Neuroscience, Inc. Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
US6673917B1 (en) 2000-09-28 2004-01-06 University Of Ottawa Antisense IAP nucleic acids and uses thereof
US20040253728A1 (en) * 2000-11-10 2004-12-16 Claes Gustafsson New method
AU2002219707A1 (en) * 2000-12-04 2002-06-18 Primagen B.V. Testing endosymbiont cellular organelles and compounds identifiable therewith
US6573051B2 (en) * 2001-03-09 2003-06-03 Molecular Staging, Inc. Open circle probes with intramolecular stem structures
US6544958B2 (en) 2001-03-26 2003-04-08 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government Therapy of respiratory influenza virus infection using free and liposome-encapsulated ribonucleotides
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
EP1432823A4 (en) * 2001-08-30 2005-03-02 Univ Emory MITOCHONDRIAL BIOLOGICAL EXPRESSION ARRAYS
JP5201834B2 (ja) 2003-05-21 2013-06-05 アンデス バイオテクノロジーズ ソシエダード アノニマ 前癌と癌細胞用のマーカー、及び前記細胞の増殖阻害方法
US7374927B2 (en) * 2004-05-03 2008-05-20 Affymetrix, Inc. Methods of analysis of degraded nucleic acid samples

Also Published As

Publication number Publication date
JP5775057B2 (ja) 2015-09-09
CA2526639C (en) 2018-03-20
BRPI0410789B8 (pt) 2021-05-25
US9359648B2 (en) 2016-06-07
EP2270159A1 (en) 2011-01-05
EP1625142B1 (en) 2011-04-20
DK2270159T3 (en) 2015-04-20
US8895719B2 (en) 2014-11-25
ATE506437T1 (de) 2011-05-15
US20060241033A1 (en) 2006-10-26
US20150064700A1 (en) 2015-03-05
JP5201834B2 (ja) 2013-06-05
US8318686B2 (en) 2012-11-27
WO2005001030A2 (en) 2005-01-06
EP2264170A1 (en) 2010-12-22
US20130149371A1 (en) 2013-06-13
WO2005001030A3 (en) 2005-12-22
ES2536002T3 (es) 2015-05-19
JP2015096069A (ja) 2015-05-21
EP1625142A4 (en) 2007-04-04
US20160304971A1 (en) 2016-10-20
ES2365511T3 (es) 2011-10-06
PL1625142T3 (pl) 2011-11-30
ES2618210T3 (es) 2017-06-21
US20210348236A1 (en) 2021-11-11
US9903000B2 (en) 2018-02-27
CA2526639A1 (en) 2005-01-06
HUE032575T2 (en) 2017-10-30
US10876166B2 (en) 2020-12-29
EP2264170B1 (en) 2017-02-08
EP1625142A2 (en) 2006-02-15
JP2007519395A (ja) 2007-07-19
PL2264170T3 (pl) 2017-08-31
US20180340232A1 (en) 2018-11-29
BRPI0410789B1 (pt) 2020-11-10
DK2264170T3 (en) 2017-03-20
JP2013066478A (ja) 2013-04-18
MXPA05012620A (es) 2006-05-25
PL2270159T3 (pl) 2015-08-31
DK1625142T3 (da) 2011-08-08
DE602004032329D1 (de) 2011-06-01
EP2270159B1 (en) 2015-01-07

Similar Documents

Publication Publication Date Title
Ahmed et al. Ocular neuroprotection by siRNA targeting caspase-2
ES2558962T3 (es) Polinucleótido bicatenario
ES2703914T3 (es) Marcadores de diagnóstico para el tratamiento de los trastornos proliferativos celulares con inhibidores de la telomerasa
Xu et al. MicroRNA-124 improves functional recovery and suppresses Bax-dependent apoptosis in rats following spinal cord injury
KR20030074639A (ko) Ｅｒｃｃ1 발현에 기초한 화학요법을 결정하는 방법
Dubuc et al. The epigenetics of brain tumors
Brem et al. UVA photoactivation of DNA containing halogenated thiopyrimidines induces cytotoxic DNA lesions
ES2939509T3 (es) Procedimiento para la identificación de la sensibilidad de un paciente a una terapia de inhibición de la telomerasa
Ebenryter‐Olbińska et al. Versatile method for the site‐specific modification of DNA with boron clusters: anti‐epidermal growth factor receptor (EGFR) antisense oligonucleotide case
Zhou et al. Upconverting nanoparticles based nanodevice for DNAzymes amplified miRNAs detection and artificially controlled chemo-gene therapy
BRPI0410789A (pt) moléculas de ácido nucleico, composto ou oligonucleotìdeo, composição farmacêutica, métodos para induzir a morte da célula pré-cancerosa ou cancerosa em células ou tecidos, para tratar um ser humano ou animal suspeito de ter pré-cáncer ou cáncer, para melhorar a eficácia de um tratamento de cáncer com medicamento quimioterapêutico e de hibridização para distinguir entre células normais, pré-cancerosas ou cancerosas, kit, e, método de hibridização in situ para determinar a localização da célula do rna quimérico mitocondrial anti-sentido ou sentido no citoplasma, núcleo e nucléolo das células presentes na amostra
Yuan et al. Construction of an endogenous ATP-driven self-dissociated DNA nanoflower for rapid imaging of multiple long noncoding RNAs and chemotherapy
Peng et al. Nucleotide excision repair of a DNA interstrand cross-link produces single-and double-strand breaks
Tsellou et al. Hypermethylation of CpG islands in the promoter region of the p15INK4B gene in childhood acute leukaemia
Zhang et al. Cantharidin modulates the E2F1/MCM7-miR-106b-93/p21-PTEN signaling axis in MCF-7 breast cancer cells
Yu et al. Excision repair of BPDE-adducts in human lymphocytes: diminished capacity associated with ERCC1 C8092A (rs3212986) polymorphism
WO2012088067A1 (en) Methods for predicting and/or determining responsiveness to a histone deacetylase (hdac) inhibitor
ES2369957T3 (es) Detección de gérmenes asociados a periodontitis.
RU2553349C1 (ru) Олигодезоксирибонуклеотидный ингибитор днк-метилтрансферазы 1 человека
Saini et al. Molecular mechanistic approach to reveal decitabine's effect on DNMT gene modulation and its inhibitory role in heavy metal-induced proliferation in urinary bladder cancer cell line
RU2490638C1 (ru) Способ прогнозирования развития в-клеточных и т-клеточных неходжкинских лимфом
CN112961918B (zh) lncRNA在口腔癌诊断和治疗中的应用
ES2716391T3 (es) Método para predecir la respuesta al tratamiento con radioterapia combinada con quimioterapia basada en cisplatino
ES3032258B2 (es) ARNs largos no codificantes mitocondriales como biomarcadores de cáncer colorrectal
Tütüncü Investigating the Interactions of Azacyanines with Triplex Nucleic Acids

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ANDES BIOTECHNOLOGIES S.A. (CL)

Free format text: TRANSFERIDO DE: BIOS CHILE, I.G.S.A.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25A Requested transfer of rights approved

Owner name: ANDES BIOTECHNOLOGIES GLOBAL, INC. (US)

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/05/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22B Petition not considered [chapter 22.2 patent gazette]

Free format text: PI0410789-6: NAO CONHECIDA A PETICAO NO 870210067667, DE 26/07/2021, EM VIRTUDE DO DISPOSTO NO ART. 219 , INCISO II DA LPI

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2776 DE 19-03-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.